HK1087103A1 - Anilinopyrazole derivatives useful for the treatment of diabetes - Google Patents

Anilinopyrazole derivatives useful for the treatment of diabetes

Info

Publication number
HK1087103A1
HK1087103A1 HK06107103.3A HK06107103A HK1087103A1 HK 1087103 A1 HK1087103 A1 HK 1087103A1 HK 06107103 A HK06107103 A HK 06107103A HK 1087103 A1 HK1087103 A1 HK 1087103A1
Authority
HK
Hong Kong
Prior art keywords
diabetes
treatment
derivatives useful
anilinopyrazole
anilinopyrazole derivatives
Prior art date
Application number
HK06107103.3A
Other languages
English (en)
Inventor
Joachim Rudolph
Louis-David Cantin
Steven Magnuson
William Bullock
Ann-Marie Bullion
Libing Chen
Chih-Yuan Chuang
Sidney Liang
Dyuti Majumdar
Herbert Ogutu
Alan Olague
Ning Qi
Philip L Wickens
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of HK1087103A1 publication Critical patent/HK1087103A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
HK06107103.3A 2002-11-27 2006-06-21 Anilinopyrazole derivatives useful for the treatment of diabetes HK1087103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US49821403P 2003-08-27 2003-08-27
PCT/US2003/037829 WO2004050651A1 (fr) 2002-11-27 2003-11-25 Derives d'anilinopyrazole destines au traitement du diabete

Publications (1)

Publication Number Publication Date
HK1087103A1 true HK1087103A1 (en) 2006-10-06

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107103.3A HK1087103A1 (en) 2002-11-27 2006-06-21 Anilinopyrazole derivatives useful for the treatment of diabetes

Country Status (17)

Country Link
US (2) US7265144B2 (fr)
EP (1) EP1567517A1 (fr)
JP (1) JP2006510728A (fr)
KR (1) KR20050085170A (fr)
AR (1) AR042067A1 (fr)
AU (2) AU2003295890A1 (fr)
BR (1) BR0316723A (fr)
CA (1) CA2507186A1 (fr)
HK (1) HK1087103A1 (fr)
HN (1) HN2003000379A (fr)
MX (1) MXPA05004621A (fr)
MY (1) MY141528A (fr)
PE (1) PE20040907A1 (fr)
PL (1) PL377164A1 (fr)
TW (1) TW200418803A (fr)
UY (1) UY28098A1 (fr)
WO (2) WO2004050650A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009531A1 (en) * 2004-05-20 2008-01-10 Bayer Pharmaceuticals Corporation 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes
ES2395952T3 (es) * 2005-03-16 2013-02-18 Toyama Chemical Co., Ltd. Nuevo derivado del ácido antranílico o una sal del mismo
US7750004B2 (en) * 2005-07-07 2010-07-06 Abbott Laboratories Apoptosis promoters
EP1928455A1 (fr) * 2005-08-31 2008-06-11 Bayer Healthcare, LLC Derives d'anilinopyrazole utilises dans le traitement du diabete
WO2007129195A2 (fr) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazoles
EP2049493B1 (fr) 2006-07-31 2012-03-21 Cadila Healthcare Limited Composés appropriés comme modulateurs du hdl
CA2663366C (fr) 2006-10-02 2012-02-07 Irm Llc Composes et compositions utilises en tant qu'inhibiteurs de proteine kinase
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
WO2009045761A1 (fr) * 2007-09-28 2009-04-09 Absolute Science, Inc. Composés et procédés permettant de traiter des maladies dépendant de métalloprotéases à zinc matricielles
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
CA2737437A1 (fr) * 2008-09-19 2010-03-25 Absolute Science, Inc. Procedes de traitement d'une affection liee a une toxine botulique chez un sujet
AU2009295967A1 (en) 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
EP2871179A4 (fr) * 2012-07-03 2016-03-16 Ono Pharmaceutical Co Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
EP3663287B1 (fr) 2013-12-23 2023-09-20 Amazentis SA Synthèse d'urolithines à l'échelle du procédé
CN107635967B (zh) 2015-06-18 2021-03-26 日本曹达株式会社 二芳基唑化合物和有害生物防除剂
CA3066680C (fr) * 2017-05-26 2022-04-12 Dongfang Shi Inhibiteur de l'urat1 stimulant l'excretion urinaire
WO2020227368A1 (fr) * 2019-05-08 2020-11-12 Trustees Of Boston University Inhibiteurs de hsp90 et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT649407A (fr) 1960-04-14
US3790576A (en) * 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
WO1993019054A1 (fr) 1992-03-26 1993-09-30 Dowelanco Nitro-anilines n-heterocycliques utilisees comme fongicides
ES2219670T3 (es) 1994-11-10 2004-12-01 Millennium Pharmaceuticals, Inc. Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis.
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
ATE410415T1 (de) * 2003-02-27 2008-10-15 Smithkline Beecham Corp Neue verbindungen

Also Published As

Publication number Publication date
US7265144B2 (en) 2007-09-04
AU2003295890A1 (en) 2004-06-23
EP1567517A1 (fr) 2005-08-31
US20080064734A1 (en) 2008-03-13
WO2004050650A1 (fr) 2004-06-17
UY28098A1 (es) 2004-06-30
BR0316723A (pt) 2005-10-18
MY141528A (en) 2010-05-14
HN2003000379A (es) 2005-12-20
TW200418803A (en) 2004-10-01
PL377164A1 (pl) 2006-01-23
CA2507186A1 (fr) 2004-06-17
US20040157904A1 (en) 2004-08-12
KR20050085170A (ko) 2005-08-29
MXPA05004621A (es) 2005-06-08
PE20040907A1 (es) 2005-01-27
AU2003297565A1 (en) 2004-06-23
WO2004050651A1 (fr) 2004-06-17
AR042067A1 (es) 2005-06-08
JP2006510728A (ja) 2006-03-30

Similar Documents

Publication Publication Date Title
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL218909A0 (en) Treatment of diabetes
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
IL165257A0 (en) 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obestity anddyslipidemia
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IL209352A0 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
GB0329874D0 (en) Compounds useful for the treatment of diseases
NO20045554L (no) Fremgangsmate for behandling av diabetes
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
AP2005003336A0 (en) Combination for the treatment of ADHD
EP1750698A4 (fr) Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
PL377464A1 (pl) Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
IL165242A0 (en) Treatment for diabetes
AU2003251904A1 (en) Combinations of drugs for the treatment of neoplasms
AU2003233820A1 (en) Method for the treatment of starch
IL165137A0 (en) Process for the preparation of thioalkylamine derivatives
AU2003270683A8 (en) Compounds for the treatment of premature ejaculation
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
GB0212790D0 (en) Medicament for the treatment of diabetes
HK1087027A1 (en) Use of 2H-Ä1, 3Ü-oxazinoÄ3,2-AÜindole derivatives for the treatment of neuropathic pain
ZA200605302B (en) Use of pentadienoic acid derivatives for the treatment of hyperuricemia

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121125